Trial Profile
An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 9496 (Primary) ; Fulvestrant
- Indications Early breast cancer
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 31 Mar 2020 Primary endpoint (Pharmacodynamics changes to estrogen receptor (ER) expression following treatment with AZD9496 or fulvestrant) has not been met.
- 31 Mar 2020 Results published in the Clinical Cancer Research
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.